Is AUNA S.A. a Solid Investment Opportunity Post Q4 Earnings?

Free cash flow rose 35% to PEN 582m and cash and equivalents increased ~42% to PEN 335m after an $825m refinancing; net leverage remained 3.6x Net Debt/Adj. EBITDA with a target to fall below 3x over the medium term. Q4 performance was led by Peru (revenues +11%, adjusted EBITDA +14%) and Colombia (revenues +6%), while Mexico shows early stabilization with oncology revenues up ~35% sequentially; shares have rallied 24.6% since the earnings release to $5.98 and are +21.1% YTD.

Analysis

Scale in a vertically integrated healthcare platform provides a non-linear margin lever: the insurer-to-provider feed lets management reprice high-complexity episodes and capture a larger share of patient lifetime value, not just single-visit revenue. If management can protect physician participation and steer higher-margin cases into its own facilities, EBITDA expansion will compound faster than linear revenue growth because fixed-cost absorption and downstream ancillary yield kick in.

The principal execution risk is concentrated operationally and regionally — payment-term renegotiations, physician network churn, and local FX/insurance regulation can swing free cash conversion within a quarter or two. Key catalysts to watch over the next 3–12 months are payer contract renewals, rollout of packaged-service distribution into self-pay cohorts, and the first cash flows from any newly opened outpatient capacity; misses on any of these will compress multiples quickly.

Second-order dynamics create optionality and threats: successful value-based pilots can become an M&A playbook (bolt-on acquisitions of small chains to densify networks), while underperformance would invite competitor poaching and capitulation of smaller rivals that could paradoxically create consolidation opportunities. Finally, the recent technical momentum likely draws liquidity providers and retail flows — helpful on the way up but amplifying downside on any guidance slip, so manage position sizing around catalyst dates.

Key Decisions for Investors

• Long AUNA equity (12-month target): Initiate a core position sized 3–5% of equity allocation with a 12-month target return of 30–50% and a hard stop-loss at -20%. Rationale: optionality from margin expansion and consolidation; trim into outsized rallies after positive payer renewals.
• Relative-value pair — Long AUNA / Short AVAH (12 months): Size net exposure 2–3% of portfolio (long leg larger if conviction high). Expect pair alpha ~25–35% if AUNA’s operational recovery sustains and AVAH’s execution remains weak; risk if macro healthcare demand falls broadly.
• Options collar on AUNA (18 months): Buy long-dated calls (LEAPs) ~12–18 months out and fund with nearer-term OTM call sales to reduce premium. This provides 3–5x upside leverage with defined downside limited to paid premium; roll into catalysts (payer renewals, new capacity ramp).
• Credit/currency hedge (3–12 months): Prefer exposure to local-currency corporate debt over USD-duration paper to reduce FX mismatch, and hedge MXN/PEN exposure if funding USD assets. Reward: protect free-cash-flow converted to hard currency; risk: local rates volatility and basis cost.